combination immune checkpoint inhibitors for the … · title: combination immune checkpoint...

1
Combination Immune Checkpoint Inhibitors for the Treatment of Human Colon Carcinoma in NSG Mice Engrafted with Human PBMC. Martin R. Graf; Jason M. Davis; Anya Avrutskaya; Lynnelle Thorpe; Mark Ellison; Vivek Mahajan; Thi Bui; Aidan Synnott; Robert J. Mullin and Paula L. Miliani de Marval. Charles River Discovery Services, Morrisville, NC, USA 4 SUMMARY and CONCLUSIONS 2 MATERIALS AND METHODS PK and Efficacy studies : Female NSG TM mice (Jackson laboratory), were 8-10 weeks were engrafted with human peripheral blood mononuclear cells (PBMC) at 3x10 7 cell/animal (Hemacare; PBMC-HLA-A*01/01, PBMC-HLA-A*01/02; PBMC- HLA- A*03/24). Seven days post engraftment, animals were implanted with 5x10 6 RKO tumor cells in 50% Matrigel, subcutaneously in the right flank. Dosing began on Day 1 in mice with established RKO tumors (group mean 70 mm 3 ). The study endpoint was a tumor volume of 1500 mm 3 in the control group for the RKO I study and Day 18 in the RKO II study in which samples were collected for flow cytometry analysis. Treatment outcome was based on percent tumor growth inhibition (%TGI), defined as the percent difference between the median tumor volumes (MTVs) of treated and control mice. Percent TGI was calculated using the following formula: %TGI = [1-(MTVdrug treated/MTVcontrol)] x 100. The results of two independent studies are shown here. Statistical Significance was determined using the Mann- Whitney U test. Flow Cytometry Analysis Peripheral blood was collected in tubes containing K 2 EDTA and immune cell populations were analyzed by flow cytometry. All data were collected on a FACSCanto II (BD) and analyzed with FlowJo software (Tree Star, Inc.). Initial sequential gating on singlets (FSC-H vs. FSCA), leukocytes (SSC-A vs. FSC-A) and live cells was performed followed by identification of immune cells populations based upon the following phenotype markers: hCD45+; CD4 (hCD45+CD3+CD4+), CD8 (hCD45+CD3+CD8+), T cell populations were further defined as effector (EFF) and effector memory (EM) based upon CCR7 and CD45RO expression. The cell lines A375, A2058, SK-MEL-24, SK-MEL- 5, HT-1080, Colo205, RKO, HCT116, MDA-MB-231, Calu6, HCC827, SKOV3, were analyzed by flow cytometry for the expression of PD-L1 and PDL-2. 1 ABSTRACT Over the past decade there has been an increasing interest for preclinical models useful for evaluating the efficacy of checkpoint inhibition-based cancer immunotherapies. Moreover, the recently developed humanized mouse models offer a unique tool to evaluate the anti-tumor response of the human immune system to checkpoint inhibitors. In a model development study we established that animals successfully engrafted with huPBMC developed graft versus host disease (GvHD) in 5 to 6 weeks. Here we present the response to the checkpoint inhibitors pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in the human RKO colon carcinoma (HLA-A* 01) xenograft model following the engraftment of HLA matched huPBMC in NSG mice. Combination of pembrolizumab with ipilimumab therapy resulted in a significant inhibition of tumor growth. Analysis of the human immune cell subsets showed the major fraction of the human CD45 cells were T-cells. There was a significant increase in the T-cell population of the combination treatment group as compared to the control group in which CD8 T-cells predominated. In summary, this study supports the use of huPBMC-NSG mouse model to test the tumor response to immune- checkpoint based therapies as it shows significant tumor growth inhibition associated with CD8 T expansion. In addition, this study demonstrates that there is a therapeutic window to evaluate cancer treatments before the onset of xenogeneic GvHD in this model. 3 RESULTS 5 ACKNOWLEDGEMENTS # 161 Cell line % PD-L1 + % PD-L2 + A375 melanoma 66.8 0.0 HT-1080 fibrosarcoma 98.2 0.4 SK-MEL-5 melanoma 9.9 0.0 HCC827 lung 94.8 0.6 Colo205 colon 40.8 0.0 SK-MEL-24 melanoma 8.4 0.0 RKO colon 99.9 22.0 MDA-MB-231 breast 99.7 0.7 HCT116 colon 60.5 0.0 Calu6 lung 53.8 0.0 SKOV3 ovarian 73.1 0.8 A2058 melanoma 55.0 0.6 Table I: Evaluation of the Expression of PD-L1, PD-L2, In Human Cell Lines by Flow Cytometry Analysis Figure 1: Evaluation of multiple hPBMC donors for engraftment levels in NSG mice. Group n Regimen 1 Donor Cell # Injection Site Schedule 1 4 PBMC Donor 1 A*01/01 3 x 10 7 iv day 1 2 4 PBMC Donor 2 A*01/02 3 x 10 7 iv day 1 3 4 PBMC Donor 3 A*01/02 3 x 10 7 iv day 1 4 4 PBMC Donor 4 A*03/24 3 x 10 7 iv day 1 Treatment Regimen MTV (n) Statistical Significance Group n PBMC: A*01/01 Agent μg/animal Route Schedule Day 18 %TGI vs G1 vs G4 1 5 3 x 10 7 Polyclonal Human IgG 200 ip biwk x 3 936 (5) --- --- --- 2 6 3 x 10 7 ipilimumab 100 ip biwk x 3 600 (6) 36 p<0.01 p<0.05 3 5 3 x 10 7 pembrolizumab 100 ip biwk x 3 320 (5) 66 p<0.01 ns 4 6 3 x 10 7 ipilimumab pembrolizumab 100 100 ip ip biwk x 3 320 (6) 66 p<0.01 --- Treatment Regimen Group n PBMC: A*01/01 Agent μg/animal Route Schedule 1 8 3 x 10 7 Polyclonal Human IgG 200 ip biwk x 3 2 8 3 x 10 7 Ipilimumab (anti-hCTLA-4) pembrolizumab (anti-hPD-1) 100 100 ip ip biwk x 3 d18 d15 Tx Tx -12d d4 d11 d8 d1 -5d HuPBMC 50-80mg Tumors Start Tx Tx Tx Tx Tumor implant d13 d27 End Treatment Regimen MTV (n) Statistical Grou p n PBMC Agent μg/animal Route Schedule Day 37 %TGI Significance 1 7 No Polyclonal Human IgG 100 ip biwk x 3 1639 (7) --- --- 2 7 No ipilimumab 100 ip biwk x 3 1711 (7) -4 ns 3 7 No pembrolizumab 100 ip biwk x 3 2168 (7) -32 p<0.05 4 7 No ipilimumab pembrolizumab 100 100 ip ip biwk x 3 2013 (7) -23 ns Control IgG Ipi Pembro Pembro +Ipi Treatment Table for PK study Mean Body Weight of Engrafted NSG Mice Identification of Immune Cell Subsets from Blood Samples Collected on Days 8 and 22 from NSG Humanized Mice Representative Immune Cell profile of hPBMC Prior to Engraftment hCD45% hCD3% hCD4% hCD8% Day 8 Day 22 Day 8 Day 22 Day 22 Day 22 Day 8 Day 22 PBMC Donor 1 A*01/01 ND 64.1 ± 6.3 ND 56.1 ± 7.3 ND 41.9 ± 6.7 ND 11.4 ± 1.3 PBMC Donor 2 A*01/02 14.2 ± 1.6 40.8± 7.4 93.1 ± 0.7 98.8 ± 0.4 65.0 ± 1.4 39.1 ± 8.8 29.5 ± 1.4 56.6 ± 8.2 PBMC Donor 3 A*01/02 12.45 ± 1.5 75.8 ± 4.7 85.9 ± 1.3 97.6 ± 0.4 35.9 ± 2.0 45.7 ± 5.4 52.4 ± 1.2 49.5 ± 4.5 PBMC Donor 4 A*03/24 2.5 ± 1.2 70.4 ± 7.6 90.4 ± 0.6 96.3 ± 0.8 39.9 ± 8.0 59.1 ± 5.3 48.4 ± 4.3 36.5 ± 4.3 Figure 2: Evaluation of the Efficacy of Ipililumab (anti-hCTLA-4) and Pembrolizumab (anti-hPD-1) Combination Therapy in the Human RKO Colorectal Carcinoma in Humanized NSG Mice. Protocol Design in the RKO Study I Treatment MTV(8): 1759 mm 3 MTV(8): 1077 mm 3 TGI: 42%) * * * (p< 0.001) Mean Tumor Volume Growth and Body Weight Figure 3: Evaluation of the Efficacy of Ipililumab (anti-hCTLA-4) and Pembrolizumab (anti-hPD-1) Alone and in Combination in the Human RKO Colorectal Carcinoma in Humanized NSG Mice. Protocol Design and Tumor Growth Inhibition in humanized NSG mice in the RKO II Study Protocol Design and Tumor Growth Inhibition in NSG mice in the RKO III Study Mean Tumor Volume Growth in the RKO II Study Percent hCD45 in Blood from Humaniized NSG Mice in the RKO II Study Mean Tumor Volume Growth in the RKO III Study Using Non-Engrafted NSG Mice Effector Memory CD8 T cells Predominate in the RKO Tumors and is Associated with Reduced PD-1 Expression in the Pembrolizumab Treatment Groups Multiple hPBMC donors were evaluated for engraftment in NSG mice and demonstrated similar levels of circulating hCD45 leukocytes. By day 22 most of the hCD45 cells were CD3+ distributed between CD4 and CD8 subsets. There is a limited therapeutic window in the hPBMC-NSG model which is donor dependent The RKO colorectal carcinoma model is responsive to pembrolizumab alone and in combination with ipililumab. Ipililumab produced a modest, yet significant tumor growth inhibition in the RKO humanized NSG model. The response to pembrolizumab and ipililumab therapy is only observed in humanized animals. We would like to thank Alan Meshaw and Shane Henry their for their valued contribution to the graphical and statistical presentation. hCD45 Control IgG hCD45 gate FSC Pembrolizumab hCD45 gate Naive Cen. Mem. Effector Eff. Men. Control IgG Naive Cen. Mem. Effector Eff. Men. Pembrolizumab CCR7 FSC Counts Control IgG PD-1 Pembrolizumab Counts Naive Cen. Mem. Effector Eff. Men. Ipilimumab Naive Cen. Mem. Effector Eff. Men. Ipi + Pembro CCR7 FSC Counts Ipilimumab PD-1 Counts Ipi + Pembro

Upload: phungngoc

Post on 22-Jul-2018

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Combination Immune Checkpoint Inhibitors for the … · Title: Combination Immune Checkpoint Inhibitors for the Treatment of Human Colon Carcinoma in NSG Mice Engrafted with Human

Combination Immune Checkpoint Inhibitors for the Treatment of Human Colon Carcinoma in NSG Mice Engrafted with Human PBMC. Martin R. Graf; Jason M. Davis; Anya Avrutskaya; Lynnelle Thorpe; Mark Ellison; Vivek Mahajan; Thi Bui; Aidan Synnott; Robert J. Mullin and Paula L. Miliani de Marval. Charles River Discovery Services, Morrisville, NC, USA

4 SUMMARY and CONCLUSIONS

2 MATERIALS AND METHODS PK and Efficacy studies: Female NSGTM mice (Jackson laboratory), were 8-10 weeks were engrafted with human peripheral blood mononuclear cells (PBMC) at 3x107 cell/animal (Hemacare; PBMC-HLA-A*01/01, PBMC-HLA-A*01/02; PBMC- HLA- A*03/24). Seven days post engraftment, animals were implanted with 5x106 RKO tumor cells in 50% Matrigel, subcutaneously in the right flank. Dosing began on Day 1 in mice with established RKO tumors (group mean 70 mm3). The study endpoint was a tumor volume of 1500 mm3 in the control group for the RKO I study and Day 18 in the RKO II study in which samples were collected for flow cytometry analysis. Treatment outcome was based on percent tumor growth inhibition (%TGI), defined as the percent difference between the median tumor volumes (MTVs) of treated and control mice. Percent TGI was calculated using the following formula: %TGI = [1-(MTVdrug treated/MTVcontrol)] x 100. The results of two independent studies are shown here. Statistical Significance was determined using the Mann-Whitney U test. Flow Cytometry Analysis Peripheral blood was collected in tubes containing K2EDTA and immune cell populations were analyzed by flow cytometry. All data were collected on a FACSCanto II (BD) and analyzed with FlowJo software (Tree Star, Inc.). Initial sequential gating on singlets (FSC-H vs. FSCA), leukocytes (SSC-A vs. FSC-A) and live cells was performed followed by identification of immune cells populations based upon the following phenotype markers: hCD45+; CD4 (hCD45+CD3+CD4+), CD8 (hCD45+CD3+CD8+), T cell populations were further defined as effector (EFF) and effector memory (EM) based upon CCR7 and CD45RO expression. The cell lines A375, A2058, SK-MEL-24, SK-MEL-5, HT-1080, Colo205, RKO, HCT116, MDA-MB-231, Calu6, HCC827, SKOV3, were analyzed by flow cytometry for the expression of PD-L1 and PDL-2.

1 ABSTRACT Over the past decade there has been an increasing interest for preclinical models useful for evaluating the efficacy of checkpoint inhibition-based cancer immunotherapies. Moreover, the recently developed humanized mouse models offer a unique tool to evaluate the anti-tumor response of the human immune system to checkpoint inhibitors. In a model development study we established that animals successfully engrafted with huPBMC developed graft versus host disease (GvHD) in 5 to 6 weeks. Here we present the response to the checkpoint inhibitors pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in the human RKO colon carcinoma (HLA-A* 01) xenograft model following the engraftment of HLA matched huPBMC in NSG mice. Combination of pembrolizumab with ipilimumab therapy resulted in a significant inhibition of tumor growth. Analysis of the human immune cell subsets showed the major fraction of the human CD45 cells were T-cells. There was a significant increase in the T-cell population of the combination treatment group as compared to the control group in which CD8 T-cells predominated. In summary, this study supports the use of huPBMC-NSG mouse model to test the tumor response to immune-checkpoint based therapies as it shows significant tumor growth inhibition associated with CD8 T expansion. In addition, this study demonstrates that there is a therapeutic window to evaluate cancer treatments before the onset of xenogeneic GvHD in this model.

3 RESULTS

5 ACKNOWLEDGEMENTS

# 161

Cell line % PD-L1 + % PD-L2 +

A375 melanoma 66.8 0.0 HT-1080 fibrosarcoma 98.2 0.4 SK-MEL-5 melanoma 9.9 0.0

HCC827 lung 94.8 0.6 Colo205 colon 40.8 0.0

SK-MEL-24 melanoma 8.4 0.0 RKO colon 99.9 22.0

MDA-MB-231 breast 99.7 0.7 HCT116 colon 60.5 0.0

Calu6 lung 53.8 0.0 SKOV3 ovarian 73.1 0.8

A2058 melanoma 55.0 0.6

Table I: Evaluation of the Expression of PD-L1, PD-L2, In Human Cell Lines by Flow Cytometry Analysis

Figure 1: Evaluation of multiple hPBMC donors for engraftment levels in NSG mice.

Group n Regimen 1

Donor Cell # Injection Site Schedule

1 4 PBMC Donor 1 A*01/01 3 x 107 iv day 1

2 4 PBMC Donor 2 A*01/02 3 x 107 iv day 1

3 4 PBMC Donor 3 A*01/02 3 x 107 iv day 1

4 4 PBMC Donor 4 A*03/24 3 x 107 iv day 1

Treatment Regimen MTV (n) Statistical Significance

Group n PBMC: A*01/01

Agent µg/animal Route Schedule Day 18 %TGI vs G1 vs G4

1 5 3 x 107

Polyclonal Human IgG 200 ip biwk x 3 936 (5) --- --- ---

2 6 3 x 107 ipilimumab 100 ip biwk x 3 600 (6) 36 p<0.01 p<0.05

3 5 3 x 107 pembrolizumab 100 ip biwk x 3 320 (5) 66 p<0.01 ns

4 6 3 x 107

ipilimumab pembrolizumab

100 100

ip ip biwk x 3 320 (6) 66 p<0.01 ---

Treatment Regimen

Group n PBMC: A*01/01 Agent µg/animal Route Schedule

1 8 3 x 107 Polyclonal Human IgG 200 ip biwk x 3

2 8 3 x 107 Ipilimumab (anti-hCTLA-4) pembrolizumab (anti-hPD-1)

100 100

ip ip biwk x 3

d18 d15 Tx Tx

-12d d4 d11 d8 d1 -5d HuPBMC 50-80mg

Tumors Start Tx

Tx Tx Tx Tumor implant

d13 d27 End

Treatment Regimen MTV (n) Statistical

Group n PBMC Agent µg/animal Route Schedule Day 37 %TGI Significance

1 7 No Polyclonal Human IgG 100 ip biwk x 3 1639 (7) --- ---

2 7 No ipilimumab 100 ip biwk x 3 1711 (7) -4 ns

3 7 No pembrolizumab 100 ip biwk x 3 2168 (7) -32 p<0.05

4 7 No

ipilimumab pembrolizumab

100 100

ip ip

biwk x 3 2013 (7) -23 ns

Control IgG Ipi Pembro Pembro +Ipi

Treatment Table for PK study Mean Body Weight of Engrafted NSG Mice

Identification of Immune Cell Subsets from Blood Samples Collected on Days 8 and 22 from NSG Humanized Mice

Representative Immune Cell profile of hPBMC Prior to Engraftment

hCD45% hCD3% hCD4% hCD8%

Day 8 Day 22 Day 8 Day 22 Day 22 Day 22 Day 8 Day 22

PBMC Donor 1 A*01/01

ND

64.1 ± 6.3

ND

56.1 ± 7.3

ND

41.9 ± 6.7

ND

11.4 ± 1.3

PBMC Donor 2 A*01/02

14.2 ± 1.6

40.8± 7.4

93.1 ± 0.7

98.8 ± 0.4

65.0 ± 1.4

39.1 ± 8.8

29.5 ± 1.4

56.6 ± 8.2

PBMC Donor 3 A*01/02

12.45 ±

1.5

75.8 ± 4.7

85.9 ± 1.3

97.6 ± 0.4

35.9 ± 2.0

45.7 ± 5.4

52.4 ± 1.2

49.5 ± 4.5

PBMC Donor 4 A*03/24

2.5 ± 1.2

70.4 ± 7.6

90.4 ± 0.6

96.3 ± 0.8

39.9 ± 8.0

59.1 ± 5.3

48.4 ± 4.3

36.5 ± 4.3

Figure 2: Evaluation of the Efficacy of Ipililumab (anti-hCTLA-4) and Pembrolizumab (anti-hPD-1) Combination Therapy in the Human RKO Colorectal Carcinoma in

Humanized NSG Mice.

Protocol Design in the RKO Study I

Treatment

MTV(8): 1759 mm3

MTV(8): 1077 mm3

TGI: 42%)

* * *

(p< 0.001)

Mean Tumor Volume Growth and Body Weight

Figure 3: Evaluation of the Efficacy of Ipililumab (anti-hCTLA-4) and Pembrolizumab (anti-hPD-1) Alone and in Combination in the Human RKO Colorectal Carcinoma in Humanized NSG Mice.

Protocol Design and Tumor Growth Inhibition in humanized NSG mice in the RKO II Study Protocol Design and Tumor Growth Inhibition in NSG mice in the RKO III Study

Mean Tumor Volume Growth in the RKO II Study Percent hCD45 in Blood from Humaniized NSG Mice in the RKO II Study

Mean Tumor Volume Growth in the RKO III Study Using Non-Engrafted NSG Mice

Effector Memory CD8 T cells Predominate in the RKO Tumors and is Associated with Reduced PD-1 Expression in the Pembrolizumab Treatment Groups

Multiple hPBMC donors were evaluated for engraftment in NSG mice and demonstrated similar levels of circulating hCD45 leukocytes. By day 22 most of the hCD45 cells were CD3+ distributed between CD4 and CD8 subsets. There is a limited therapeutic window in the hPBMC-NSG model which is donor dependent The RKO colorectal carcinoma model is responsive to pembrolizumab alone and in combination with ipililumab. Ipililumab produced a modest, yet significant tumor growth inhibition in the RKO humanized NSG model. The response to pembrolizumab and ipililumab therapy is only observed in humanized animals.

We would like to thank Alan Meshaw and Shane Henry their for their valued contribution to the graphical and statistical presentation.

hCD

45

Control IgG hCD45 gate

FSC

Pembrolizumab hCD45 gate

Naive Cen. Mem.

Effector Eff. Men.

Control IgG

Naive Cen. Mem.

Effector Eff. Men.

Pembrolizumab CC

R7

FSC

Cou

nts

Control IgG

PD-1

Pembrolizumab

Cou

nts

Naive Cen. Mem.

Effector Eff. Men.

Ipilimumab

Naive Cen. Mem.

Effector Eff. Men.

Ipi + Pembro CC

R7

FSC

Cou

nts

Ipilimumab

PD-1

Cou

nts

Ipi + Pembro